Archive for the ‘biotech/medical’ category: Page 1734
Feb 23, 2020
Your stories from the coronavirus outbreak
Posted by Derick Lee in category: biotech/medical
The restrictions have also brought unique challenges to scientists. Some have suspended their usual research to study the coronavirus. Others have had their work or personal lives disrupted by lab closures, travel restrictions or problems sourcing equipment and reagents from suppliers in China.
In a Nature reader poll, more than 600 of you told us that the coronavirus had affected you, your colleagues and your research. These are some of your stories.
From laboratory closures to equipment shortages, researchers worldwide tell Nature how they have been affected by the epidemic. ‘No one is allowed out’: readers tell Nature about their experiences.
Feb 22, 2020
New drug could cure nearly any viral infection
Posted by Quinn Sena in category: biotech/medical
Circa 2011
Most bacterial infections can be treated with antibiotics such as penicillin, discovered decades ago. However, such drugs are useless against viral infections, including influenza, the common cold, and deadly hemorrhagic fevers such as Ebola.
Now, in a development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
Continue reading “New drug could cure nearly any viral infection” »
Feb 22, 2020
A vast range of infectious diseases, ranging from AIDS to Ebola, are now curable
Posted by Kelvin Dafiaghor in categories: biotech/medical, genetics, robotics/AI
Do you agree.
In addition, gene-editing technologies continue to advance in precision and ease of use, allowing families to treat and ultimately cure hundreds of inheritable genetic diseases.
This metatrend is driven by the convergence of: various biotechnologies (CRISPR, Gene Therapy), genome sequencing, and artificial intelligence.
Feb 22, 2020
Are China’s Coronavirus Figures Reliable?
Posted by Omuterema Akhahenda in category: biotech/medical
Taken at face value, China’s coronavirus containment strategy appears to be working. But can the official figures be trusted?
China reports that new virus cases are declining, but the data may be tied to party politics.
Feb 22, 2020
Coronavirus: northern Italian towns close schools and businesses
Posted by Prem Vijaywargi in categories: biotech/medical, business, education
Feb 22, 2020
Optimising gene editing for cancer therapy
Posted by Quinn Sena in categories: bioengineering, biotech/medical, genetics
Gene editing holds promise for the treatment of cancers that are driven by well-characterised molecular alterations. A study now provides a proof of concept for the feasibility of in vivo gene editing to correct TERT mutations in glioblastoma, providing a platform for the direct manipulation of genetic alterations to reduce tumour growth.
Feb 22, 2020
New CRISPR tool could fix almost all disease-causing DNA glitches
Posted by Quinn Sena in category: biotech/medical
The tool can precisely change any of DNA’s “letters” into any other and insert or delete any stretch of DNA — all more efficiently than previous CRISPR.
Feb 22, 2020
More than 80 clinical trials launch to test coronavirus treatments
Posted by Quinn Sena in category: biotech/medical
As HIV drugs, stem cells and traditional Chinese medicines vie for a chance to prove their worth, the World Health Organization attempts to bring order to the search.
Feb 22, 2020
Biotech firm Kymab in battle over ‘human mice’ secrets
Posted by Omuterema Akhahenda in categories: biotech/medical, law
A Cambridge-based biotech company that is creating a colony of “human” mice is locked in a Tom and Jerry-style fight with a US pharmaceutical giant.
Kymab, which is backed by the Bill and Melinda Gates Foundation and counts fund manager Neil Woodford among its investors, is seeking permission to appeal to the Supreme Court in a row over patents. It follows a ruling by the Court of Appeal earlier this year that Kymab infringed a patent belonging to US company Regeneron. A previous judgment ruled that Regeneron’s patent was insufficient.
The legal tussle relates to Kymab’s “Kymouse” work, in which it manipulates the genome of mice. Kymab removes the genes that make antibodies in mice and replaces them with human antibody genes. This means that.